Cargando…
On the role of endogenous neurotoxins and neuroprotection in Parkinson's disease
For 50 years ago was introduced L-3,4-dihydroxyphenylalanine (L-dopa) in Parkinson's disease treatment and during this significant advances has been done but what trigger the degeneration of the nigrostriatal system remain unknown. There is a general agreement in the scientific community that m...
Autor principal: | Segura-Aguilar, Juan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5514859/ https://www.ncbi.nlm.nih.gov/pubmed/28761417 http://dx.doi.org/10.4103/1673-5374.208560 |
Ejemplares similares
-
New drug treatments show neuroprotective effects in Alzheimer's and Parkinson's diseases
por: Hölscher, Christian
Publicado: (2014) -
TFP5/TP5 peptide provides neuroprotection in the MPTP model of Parkinson's disease
por: Binukumar, BK, et al.
Publicado: (2016) -
Commentary: Gene Therapy: A Promising Approach for Neuroprotection in Parkinson's Disease?
por: Segura-Aguilar, Juan
Publicado: (2017) -
Neuroprotective effects of erythropoietin on neurodegenerative and ischemic brain diseases: the role of erythropoietin receptor
por: Hernández, Carolina Castillo, et al.
Publicado: (2017) -
Neurotoxicity and Underlying Mechanisms of Endogenous Neurotoxins
por: Cao, Yanlu, et al.
Publicado: (2021)